Hyperlipidemia in solid organ transplantation

Transplantation

Volumn 63, Issue 3, 1997, Pages 331-338

  Kobashigawa, Jon A ^a,b   Kasiske, Bertram L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; AZATHIOPRINE; BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; OKT 3; PRAVASTATIN; PREDNISONE; PROBUCOL; SIMVASTATIN; TACROLIMUS;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG INHIBITION; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; META ANALYSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION;

EID: 0031016349     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199702150-00001     Document Type: Review

References (86)

1. Pirsch JD, D'Alessandro AM, Sollinger HW, et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992; 2 (suppl 3): S238.
2. Grundy SM. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329.
3. Miller LW. Allograft vascular disease: a disease not limited to hearts. J Heart Lung Transplant 1992; 11 (3, Pt 2): S32.
4. Grady KL, Costanzo-Nordin MR, Herold LS, Sriniavasan S, Pifarre R. Obesity and hyperlipidemia after heart transplantation. J Heart Lung Transplant 1991; 10: 449.
5. Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8: 209.
6. de Groen PC. Cyclosporine, low density lipoprotein, and cholesterol. Mayo Clin Proc 1988; 63: 1012.
7. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625.
8. Becker DM, Chanberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85: 632.
9. Ibels LS, Simons LA, King JO, Williams PF, Neale FC, Stewart JK. Studies on the nature and causes of hyperlipidemia in uraemia, maintenance dialysis and renal transplantation. Q J Med 1975; 44: 601.
10. U.S. Renal Data System. USRDS 1995 annual data report. Bethesda, MD: NIH, NIDDK, 1995.
11. Bull DA, Hunter GC, Copeland JG, et al. Peripheral vascular disease in heart transplant recipients. J Vasc Surg 1992; 16: 546.
12. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. Twenty-fourth Bethesda conference: cardiac transplantation. Task force 5: complications. J Am Coll Cardiol 1993; 22: 41.
13. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience with treatment recommendations. J Am Coll Cardiol 1992; 19: 1315.
14. Kirk JK, Dupuis RE. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995; 29: 879.
15. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11: S124.
16. Farmer JA, Ballantyne CM, Frazier OH, et al. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol 1991; 18: 926.
17. Gao S-Z, Schroeder JA, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80 (suppl 3): III-100.
18. O'Neill BJ, Pflugfelder PW, Singh NR, Menkis AH, McKenzie FN, Kostuk WJ. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989; 63: 1221.
19. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 1992; 11: 9.
20. McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts: implications of pathogenesis of allograft arteriopathy. Am J Pathol 1995; 147: 293.
21. Winters GL, Kendall TJ, Radio SJ, et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant 1990; 9: 364.
22. Valantine HA. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995; 14: S234.
23. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine 1987; 66: 309.
24. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37.
25. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Metabolic changes in renal transplant patients managed with and without cyclosporine. Clin Transplant 1992; 6: 403.
26. Jung K, Neumann R, Scholz D, Nugel E. Abnormalities in the composition of serum high density lipoprotein in renal transplant recipients. Clin Nephrol 1982; 17: 191.
27. Averna MR, Barbagallo CM, Sparacino V, et al. Follow-up of lipid and apoprotein levels in renal transplant recipients. Nephron 1991; 58: 255.
28. Jung K, Scheifler A, Blank W, Scholz D, Schulze BD, Hansen C. Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. Transplantation 1988; 46: 407.
29. Dasgupta A, Powell D, Saldana S, Doria L. Elevated lipid peroxidation products and depleted transferrin levels in the plasma of kidney transplant recipients. Life Sci 1990; 46: 67.
30. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663.
31. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson MC. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995; 48: 227.
32. Arnadottir M, Thysell H, Nilsson-Ehle P. Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: ciclosporin- versus non-ciclosporin-treated patients. Am J Nephrol 1991; 11: 391.
33. Massy ZA, Bader CA, Chevalier A, et al. Serum lipoprotein (a) levels in chronic renal failure and renal transplant patients. J Nephrol 1994; 7: 229.
34. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993; 341: 268.
35. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C. Comparison of LP(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of literature. Nephron 1995; 70: 155.
36. Azrolan N, Brown CD, Thomas L, et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in renal transplant recipients. Arterioscler Thromb 1994; 14: 1393.
37. Brown JH, Anwar N, Short CD, et al. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993; 8: 863.
38. Hilbrands LB, Demacher PNM, Hoitsma AJ. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 765.
39. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; 48 (suppl 52): S-56.
40. Drheke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39 (suppl 31): S24.
41. Heule H, Keusch G, Uhlschmid G, Largiader F, Binswanger U. Kardiovasculare Krankheiten nach Nierentransplantation: eine Analyse Pradisponierender Facktoren. Schweiz Med Wochenschr 1981; 20: 709.
42. Vollmer E, Bosse A, Bogeholz J, et al. Apolipoproteins and immunohistological differentiation of cells in the arterial wall of kidneys in transplant arteriopathy. Morphological parallels with atherosclerosis. Pathol Res Pract 1991; 187: 957.
43. Raine AEG, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; suppl 2: 7.
44. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451.
45. Kasiske BL, Guijarro C, Massy ZA, Weiderkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
46. Dimeny E, Fellstrom B, Larsson E, Tufveson G, Lithell H. Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 1993; 7: 482.
47. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57: 68-72.
48. Mathe D, Adam R, Malmendier C, et al. Prevalence of dyslipidemia in liver transplant recipients. Transplantation 1992; 54: 167.
49. McDiarmid SV, Gornbein JA, Fortunat M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992; 53: 109.
50. Wiesner RH, Ludwig J, van Hoek B, Krom RAF. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14: 721.
51. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1395.
52. Steinmüller TM, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporin on glucose and lipid metabolism: a randomized trial. Transplantation 1994; 58: 669.
53. Pritzker MR, Lake KD, Reutzel TJ, et al. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. J Heart Lung Transplant 1992; 11: 415.
54. Renlund DG, Bristow MR, Crandall BG, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Lung Transplant 1989; 8: 214.
55. Keogh A, Macdonald P, Harvison A, Tichens D, Mundy J, Spratt P. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant 1992; 11: 421.
56. Kobashigawa JA, Stevenson LW, Brownfield EB, et al. Corticosteroid weaning late after cardiac transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. J Heart Lung Transplant (in press).
57. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868.
58. Shepherd J, Cobbe SM, Ford J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301.
59. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.
60. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
61. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61: 1469.
62. Wenke K, Thiery J, Meiser B, Seidel D, Reichert B. Long-term simvastatin therapy for hypercholesterolemia in heart transplant patients. Z Kardiol 1995; 84: 130.
63. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47.
64. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (suppl 4): IV-281.
65. Regazzi MB, Iacona I, Campana IC, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732.
66. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410.
67. Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20: 27.
68. Jensen RA, Lal SM, Diaz-Arias A, et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J 1995; 41(3): M704.
69. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58: 245.
70. Hidalgo L, Zambrana JL, Blanco-Molina A, et al. Lovastatin versus bezafribrate for hyperlipidemia treatment after heart transplantation. J Heart Lung Transplant 1995; 14: 461.
71. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188.
72. Sundararajan V, Cooper DKC, Muchmore J, et al. Interaction of cyclosporine and probucol in heart transplant patients. Transplant Proc 1991; 23: 2028.
73. Park JW, Vermeltfoort M, Braun P, May E, Merz M. Regression of transplant coronary artery disease during chronic HELP therapy: a case study. Atherosclerosis 1995; 115: 1.
74. Kuo PC, Kirshenbaum JM, Gordon J, et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989; 64: 631.
75. Kobashigawa JA, Brownfield ED, Stevenson LW, et al. Effects of pravastatin for hypercholesterolemia in cardiac transplant recipients [Abstract]. J Am Coll Cardiol 1993; 21: 141A.
76. Barbir M, Rose M, Kushwaha S, et al. Low-dose simvastatin for the treatment of hyperlipidemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33: 241.
77. Vanhaecke J, van Cleemput J, van Lierde J, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58: 42.
78. Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29: 235.
79. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990; 49: 95.
80. Castelao AM, Grino JM, Gilverner S, et al. HMG-CoA reductase inhibitors lovastatin and simvastatin in the treatment of hyperlipidemia after renal transplantation. Transplant Proc 1993; 25: 1043.
81. Cheung AK, DeVault GA, Gregory MC. A prospective study on treatment of hyperlipidemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1883.
82. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94.
83. Kainuma O, Asano T, Ochiai T, Isono K. Lipid disorders in renal transplant recipients. Transplant Proc 1992; 24: 1585.
84. Lye W-C, Hughes K, Leong SO, Tan CC, Lee EJC. Abnormal lipoprotein(a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 1995; 27: 977.
85. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76(2): 107A.
86. Holdaas H, Hartmann A, Stenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76(2): 102A.